Literature DB >> 16987069

Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1.

Bo Zhao1, Ning-Yi Jin, Rui-Lin Wang, Li-Shu Zhang, Ying-Jiu Zhang.   

Abstract

According to data in GenBank, a gene encoding SARS spike protein fragment 1 (S1) was synthesized. After recombination with an immunostimulatory sequence (ISS), the gene was cloned into the plasmid pIRES to produce pIRES-ISS-S1. On confirmation of the expression of S1 protein by indirect immunofluorescence assay (IFA), after the transfection of pIRES-ISS-S1 into BHK-21 cells, the DNA vaccine was repeatedly administrated to BALB/c mice. CD4+ and CD8+ spleen T lymphocytes were analyzed by flow cytometry (FCM) to evaluate T cell-mediated immune responses, the antigen-specific responses of T cells were evaluated by cytotoxic T lymphocyte (CTL) assay, and the level of IgG in antisera from immunized mice was determined by enzyme-linked immunosorbent assay. Results showed that the counts of spleen CD4+ and CD8+ T lymphocytes were increased, that the T cell-mediated immune responses showed antigen specificity, and that IgG was significantly induced with DNA vaccines pIRES-ISS-S1 and pIRES-S1 at titers of 1:320 and 1:160, respectively. These results are promising for the protective immunization of humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987069     DOI: 10.1089/vim.2006.19.518

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  3 in total

1.  Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Authors:  Lanying Du; Guangyu Zhao; Yongping Lin; Hongyan Sui; Chris Chan; Selene Ma; Yuxian He; Shibo Jiang; Changyou Wu; Kwok-Yung Yuen; Dong-Yan Jin; Yusen Zhou; Bo-Jian Zheng
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

Review 2.  Current advancements and potential strategies in the development of MERS-CoV vaccines.

Authors:  Naru Zhang; Shibo Jiang; Lanying Du
Journal:  Expert Rev Vaccines       Date:  2014-04-26       Impact factor: 5.217

3.  Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.

Authors:  Lanying Du; Guangyu Zhao; Chris C S Chan; Shihui Sun; Min Chen; Zhonghua Liu; Hongxiang Guo; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Virology       Date:  2009-08-15       Impact factor: 3.616

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.